IMDC Risk Model for Metastatic Renal Cell Carcinoma
International Metastatic RCC Database Consortium (IMDC) model. Predicts prognosis and guides first-line treatment selection in metastatic RCC.
Score interpretation
Favourable risk. Median OS ~43 months.
→ VEGF-targeted therapy or IO combination (e.g., nivolumab + ipilimumab, pembrolizumab + axitinib). Consider clinical trial.
Intermediate risk. Median OS ~23 months.
→ IO-based combination therapy preferred (nivolumab + ipilimumab or IO + VEGFR-TKI). NICE/EAU guidelines recommend IO/IO or IO/TKI combinations.
Poor risk. Median OS ~8 months.
→ IO-based therapy. Consider cytoreductive nephrectomy only in selected patients. Clinical trial enrolment. Palliative care integration.
Interpretation bands for the IMDC RCC. Apply clinical judgement and local guidance.
References
- Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
- Heng DY et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model. Lancet Oncol. 2013;14(2):141-148.
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- FLIPI — Follicular Lymphoma International Prognostic Index · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.